HEMGENIX®, the first and only FDA approved gene therapy for hemophilia B, has been proven to elevate and sustain factor IX levels for years, significantly reduce the rate of annual bleeds versus standard of care, and reduce or eliminate the need for prophylactic treatment in 94% of patients (51 out of 54) after a one-time infusionContinue reading
Author Archive: AZBio
ABOR approves establishment of College of Health Sciences at UArizona Health Sciences
The University of Arizona College of Health Sciences will focus on graduate programs to fill positions of need in the health care community.Continue reading
CSBI Releases the 2023 Life Sciences Workforce Trends Report at BIO International Convention
BOSTON, MASS., U.S.A., June 7, 2023/EINPresswire.com/ — The Coalition of State Bioscience Institutes (CSBI) releases the 2023 Life Sciences Workforce Trends Report with TEConomy Partners this week at the 2023 BIO International Convention in Boston. The biennial report provides a national snapshot of the most pressing current and anticipated talent needs of the nation’s dynamic life science industry. This year’s report distills a set of key themes sourced from 185 executive interviews and nearly 700 survey responses from companies in eighteen states and Puerto Rico, as well as an assessment of nearly 2.8M job postings from life science companies over the last four years.Continue reading
New Report Explores Latest Best Practices in State Bioscience Economic Development Initiatives
Today, the Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released a new report on the best practices in state bioscience economic development measures, “The U.S. Biosciences Industry in the States: Best Practices in Innovation, Partnerships, and Job Creation.”Continue reading
BIO-backed bills that would support startups passed by House
Two bills to create a healthy investment environment for biotech startups passed the House late May 30 with overwhelming bipartisan support. The legislation was also supported by the Biotechnology Innovation Organization (BIO).
Continue reading
ABRC Request for Grant Applications Now Open
The Arizona Biomedical Research Centre announced today that it is now accepting Letters of Intent (LOI) for a new cohort of research grants. The LOI is Phase One of a two-phase process. LOI will be accepted through June 28, 2023. Once the letters are reviewed and scored, select applicants will be invited to submit a full application.Continue reading
Five UArizona Health Sciences researchers selected for Career Development Awards
The University of Arizona Health Sciences Career Development Awards program supports the development of new research by promising young investigators. Five junior faculty members beginning independent research projects are receiving funding through the University of Arizona Health Sciences Career Development Award program.Continue reading
Serva Energy Discovers ‘Highly Promising’ New Way to Produce Cancer-killing Ac-225 Isotope
Tempe, AZ — Serva Energy, a nuclear innovation company, has developed a new production method to ramp up the supply of Actinium-225, a cancer-killing isotope in ultra-high demand by oncology researchers and pharmaceutical companies developing Targeted Alpha Therapies (TAT)—a promising step forward in the fight against cancer.Continue reading
Arizona Board of Regents announces university-led statewide effort to address critical health care workforce shortages
Today, the Arizona Board of Regents announced a comprehensive, university-led statewide effort to address critical workforce shortages among physicians, nurses and other health care professionals. Currently, it is estimated nearly 3 million Arizonans have limited access to primary care, and more than one in three Arizona hospitals face a critical staffing shortage.Continue reading
Patients will lose access to 40% of future medicines because of the IRA, new research finds.
New research released by Vital Transformation (VT) shows that the Inflation Reduction Act (IRA) will stifle the ability of companies to continue research and development across a broad range of therapeutic areas. The effects of the IRA will have a far more serious impact on the development of new medicines than has been reported, according to the research.Continue reading